Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

Kathryn E. Flynn,1 Ehab Atallah,1 Li Lin,2 Neil P. Shah,3 Richard T. Silver,4 Richard A. Larson,5 Javier Pinilla-Ibarz,6 James E. Thompson,7 Vivian G. Oehler,8 Jerald P. Radich,8 Vamsi Kota,9 Michael J. Mauro,10 Charles A. Schiffer,11 Jorge Cortes,9 and Kevin P. Weinfurt2

1Medical College of Wisconsin, Milwaukee, WI; 2Duke University School of Medicine, Durham, NC; 3University of California at San Francisco, San Francisco, CA; 4Weill Cornell Medicine, New York, NY; 5University of Chicago, Chicago, IL; 6H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 7Roswell Park Comprehensive Cancer Center, Buffalo, NY; 8Fred Hutchinson Cancer Center, Seattle, WA; 9Georgia Cancer Center at Augusta University, Augusta, GA; 10Memorial Sloan Kettering Cancer Center, New York, NY and 11Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA

Abstract

For patients with optimally treated chronic myeloid leukemia (CML), discontinuation of tyrosine kinase inhibitor (TKI) therapy can lead to treatment-free remission. In previous trials, TKI discontinuation has been associated with increased musculoskeletal pain in some patients ("withdrawal syndrome"), based on physician-reported adverse events (AE). Patient-reported pain has not been described. The Life After Stopping TKI study was a 14-site prospective, non-randomized clinical trial of TKI discontinuation. We defined increased pain after discontinuation as: (i) a physician-reported pain AE, (ii) a 2-level increase in self-reported musculoskeletal pain (4-level single item), or (iii) initiation of a medication for pain. We plotted the trajectory of patient-reported pain over time using a piecewise mixed-effects ordinal logistic model. Within 3 months of discontinuation, 35 of 172 patients (20.3%) had a physician-reported pain AE, 22 of 172 (12.8%) had an increase in self-reported pain, and 18 of 154 (11.7%) initiated a pain medication. Agreement among these measures was limited; overall, 60 of 172 patients (34.9%) had increased pain. Three patients (1.7%) restarted a TKI because of pain. The model-predicted trajectory showed an increase in pain in the first 3 months followed by a decrease, returning to baseline levels by 6 months and further decreasing after that. This trajectory was similar among patients who did and did not restart TKI, suggesting that resuming a TKI for withdrawal syndrome may be necessary for some, but other approaches to manage pain should be tried so that patients can remain in treatment-free remission when possible.

Introduction

Compared to other treatments for chronic myeloid leukemia (CML), tyrosine kinase inhibitors (TKI) are highly effective1 and less toxic.2,3 However, they are still associated with side effects, particularly fatigue and gastrointestinal symptoms.4 Moreover, TKI may be cost-prohibitive for patients, leading to non-adherence.5 For select patients who achieve a sustained deep molecular response, TKI discontinuation may lead to treatment-free remission (TFR), effectively a "cure" for CML.6 In TKI discontinuation trials, 32–67% of patients sustained TFR.7,16 For patients without sustained TFR, restarting TKI therapy was effective in restoring stable remission, including return to deep molecular response. TKI discontinuation is hypothesized to improve patient-reported symptoms and functioning, and this was recently demonstrated in the US Life After Stopping TKI (LAST) study.16,17 However, previous trials found that TKI discontinuation was unexpectedly associated with increased musculoskeletal pain for some patients, which has been called "TKI withdrawal syndrome". In these previous trials, physician-reported adverse events (AE) related to musculoskeletal pain were reported for anywhere from 10–50% of patients.18 Uncertainty about the extent of increased musculoskeletal pain associated with TKI discontinuation is compounded by the reliance on physician-reported AE. Studies with patients with solid tumor cancers have documented generally poor-to-moderate agreement between physician and patient reports of pain.19 A previous study in CML assessed physician-patient agreement on nine symptoms and found 44% agreement for musculos-
keletal pain, with physicians underestimating patient musculoskeletal pain for 42% of patients and overesti-
mating it for 14% of patients.26 To our knowledge, no pre-
vious studies have described patient-reported musculoskeletal pain after TKI discontinuation. Herein we
describe physician-reported pain-related AE and patient-
reported musculoskeletal pain, as well as their overlap, in
the context of the LAST study.

Methods
LAST was a 14-site, single-arm, prospective longitudinal
TFR study. Eligible patients had chronic-phase CML, were
aged ≥18 years, and receiving imatinib, dasatinib, nilotinib,
or bosutinib for ≥3 years with continuous documented
BCR-ABL <0.01% International Standardized by real-time
quantitative polymerase chain reaction (RQ-PCR) for ≥2
years. The study was approved by the Institutional Review
Board of each participating institution, and all patients
provided written informed consent. Additional method-
ological details are included in the Online Supplementary
Appendix and have previously been published.21

Measures
Physician-reported adverse events
AE were evaluated using the Common Terminology Criteria
for Adverse Events (CTCAE) version 4.0. We defined pain-
related AE as any grade AE that was reported after TKI
discontinuation using toxicity group “musculoskeletal and
connective tissue disorders”.

Patient-reported pain
In order to measure musculoskeletal pain, we used a
single item with four response options from the European
Organization for Research and Treatment of Cancer
(EORTC) QLQ-CML24 that asks about aches or pains in
muscles or joints. We assessed how much pain affected
daily life using the PROMIS® Pain Interference comput-
erized adaptive test.22

Pain medications
On the 3-month PRO assessment for those in TFR (off
TKI), we asked patients about changes in medications
since TKI discontinuation, including whether they had
started any new prescription or over-the-counter medi-
cations. For any “yes” responses, patients were asked to
name the medication. These responses were coded by a
physician (EA) to determine whether they were related to
pain. We included analgesics, anti-inflammatory medi-
cations, and muscle relaxants.

Statistical approach
We summarized the different measures of pain using fre-
quencies and percentages. Patients were classified as
having an indicator of increased pain after stopping TKI if
they had any of the following within 3 months of stopping:
(i) physician-reported pain AE, (ii) a ≥ 2 level increase from
their previous assessment in self-reported musculoskel-
etal pain, or (3) initiation of a medication for pain (while a
1 category increase may reflect meaningful change, be-
cause of uncertainty around what to consider a meaning-
ful change on this single item, for subsequent analyses
we selected the ≥ 2 category increase to be conservative.)
Characteristics of patients who did and did not have in-
creased pain within 3 months were compared using Wil-
coxon rank sum tests for continuous or ordinal categorical
variables and χ² tests for categorical variables. Among pa-
patients with increased pain within 3 months, we plotted
the distribution of responses over time for self-reported
musculoskeletal pain and for PROMIS Pain Interference
scores. In order to better account for missing data, we
also plotted the predicted trajectory of pain using piece-
wise mixed-effects ordinal logistic (EORTC QLQ-CML24
item on musculoskeletal pain) and a piecewise mixed-ef-
fects ordinal logistic regression model (EORTC QLQ-
CML24 item on musculoskeletal pain) and a piecewise
mixed-effects linear regression model (PROMIS Pain In-
terference) that allowed the slope to differ before and
after the 3-month visit. Random intercepts and slopes
were included in models to allow the trajectories to differ
among individual patients. For time points after 6 months,
we computed the percentage of patients with no or mild
pain. We used a 2-tailed significance level of α=0.05 for
all assessments. Statistical analyses were conducted
using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

Results
From 12/2014 to 12/2016, 173 patients from 14 US centers
were enrolled, of whom 172 had evaluable data. Median
duration of TKI therapy prior to study enrollment was
about 7 years (Table 1), similar to other studies.8,9,23

Indicators of increased pain within 3 months after TKI
discontinuation
Physician-reported pain-related adverse events
Cumulatively, 35 patients (20.4%) had physician-reported
pain-related AE in the first 3 months (Table 2), with most
happening within the first month. One month after TKI
discontinuation, physicians reported pain-related AE for
26 patients (15.1%). At 2 months, physicians reported pain-
related AE for 11 patients (6.4%), and at 3 months it was
five patients (2.9%). For most patients, the maximum pain
grade was mild (Table 3). While our study focused on in-
creased pain within 3 months, ten additional patients
(5.8%) had pain-related AE reported at time points later
than 3 months, for a total of 45 patients (26%) who had a pain-related AE after TKI discontinuation.

**Patient-reported pain**
We previously reported that for patients in the LAST study, baseline pain interference scores were the same as the average in the US general population (score of 50). Regarding musculoskeletal pain specifically, the majority of patients (77.8%) reported some musculoskeletal pain before TKI discontinuation. At baseline, 38 patients (22.2%) reported no musculoskeletal pain, 60 patients (35.1%) reported a little bit, 43 patients (25.2%) reported quite a bit, and 30 patients (17.5%) reported very much (1 missing response at baseline). Within the first 3 months after TKI discontinuation, the worst musculoskeletal pain rating reported by patients was “a little bit” for 43 patients (25%), “quite a bit” for 64 patients (37.2%), and “very much” for 57 patients (33.1%). Eight patients (4.7%) consistently reported no musculoskeletal pain between baseline and 3 months, while 62% of patients reported a ≥1 category increase in musculoskeletal pain, and 13% reported a ≥2 category increase in pain (Table 2).

**Initiation of medications for pain**
At 3 months, of the 154 patients who reported on changes in medications, 18 patients (11.7%) reported adding a

---

**Table 1. Baseline patient characteristics overall and by increased pain status (N=172).**

|                          | Values       | With increased pain N=60 | Without increased pain N=112 |
|--------------------------|--------------|--------------------------|-----------------------------|
| Age in years             | Median (range) | 61 (22-88)              | 61 (22-84)                 | 61 (26-88)                 |
| Sex, N (%)               |              |                          |                            |                            |
| Female                   | 89 (51.7)    | 37 (61.7)                | 52 (46.4)                  |
| Male                     | 83 (48.3)    | 23 (38.3)                | 60 (53.6)                  |
| Race, N (%)              |              |                          |                            |                            |
| Asian/Pacific Islander   | 5 (2.9)      | 1 (1.7)                  | 4 (3.6)                    |
| Black/African American   | 18 (10.5)    | 8 (13.3)                 | 10 (8.9)                   |
| White                    | 145 (84.3)   | 51 (85.0)                | 94 (83.9)                  |
| Other                    | 3 (1.7)      | 1 (1.7)                  | 2 (1.8)                    |
| Hispanic/Latino ethnicity, N (%) | 7 (4.1) | 1 (1.7) | 6 (5.4) |
| Education, N (%)         |              |                          |                            |                            |
| Associate degree or less | 83 (48.3)    | 26 (43.3)                | 57 (50.9)                  |
| Bachelor’s degree or more| 89 (51.7)    | 34 (56.7)                | 55 (49.1)                  |
| Health insurance, N (%)  |              |                          |                            |                            |
| Private                  | 104 (60.5)   | 35 (58.3)                | 69 (61.6)                  |
| Public                   | 56 (32.5)    | 21 (35.0)                | 35 (31.3)                  |
| Other or uninsured       | 12 (7.0)     | 4 (6.7)                  | 8 (7.1)                    |
| TKI prior to discontinuation, N (%) |         |                          |                            |                            |
| Imatinib                 | 102 (59.3)   | 36 (60.0)                | 66 (58.9)                  |
| Nilotinib                | 39 (22.7)    | 13 (21.7)                | 26 (23.2)                  |
| Dasatinib                | 27 (15.7)    | 10 (16.7)                | 17 (15.2)                  |
| Bosutinib                | 4 (2.3)      | 1 (1.7)                  | 3 (2.7)                    |
| Duration of TKI treatment, months | Median (range) | 83.0 (36.1-199.1) | 83.1 (36.1-199.1) | 83.0 (36.8-182.9) |
| PROMIS Pain interference, mean (SD) | 50.7 (10.0) | 51.9 (10.4) | 50.0 (9.8) |
| PROMIS Fatigue, mean (SD) | 52.9 (9.9)  | 54.1 (10.0) | 52.3 (9.9) |
| PROMIS Physical function, mean (SD) | 47.3 (8.3) | 47.1 (7.9) | 47.4 (8.6) |
| PROMIS Depression, mean (SD) | 48.8 (8.0) | 48.9 (8.1) | 48.8 (8.0) |
| PROMIS Anxiety, mean (SD) | 50.4 (10.0) | 50.6 (8.3) | 50.3 (8.7) |
| PROMIS Sleep disturbance, mean (SD) | 49.7 (8.2) | 49.8 (8.0) | 49.7 (8.4) |
| PROMIS Social roles, mean (SD) | 51.1 (9.6) | 50.5 (9.2) | 51.4 (9.8) |

TKI: tyrosine kinase inhibitor; SD: standard deviation.
medication for pain, including eight (5.2%) who started an over-the-counter medication and 11 (7.1%) who started a prescription medication; one patient reported starting both over-the-counter and prescription medications for pain.

**Agreement among indicators of increased pain**

Agreement between physician-reported pain-related AE and patient-reported pain varied depending on the threshold considered for increase in patient-reported pain (Table 2; Online Supplementary Table S1). There was slightly better agreement between patients and physicians regarding the presence of increased pain using a ≥1 level increase (14%) compared to considering a ≥2 level increase (4%); however, there was also worse agreement regarding the absence of increased pain (31% agreement for a ≥1 level increase vs. 71% for a ≥2 level increase), resulting in a better overall agreement for a ≥2 level increase (75%) compared to a ≥1 level increase (45%). The cross-tabulation of AE grade and patient-reported increase in musculoskeletal pain is shown in Table 3. Although physicians and patients reported the symptoms using different methodologies and scales, Table 3 suggests that physicians’ ratings reflect under-reporting (values in the upper right cells) more than over-reporting (values in the lower left cells).

Using the ≥2 level increase in patient-reported pain, 45 patients (26%) had a single indicator of increased pain (AE, increase on PRO measure, or reported new medication), and 15 patients (9%) had more than one indicator of increased pain, for a total of 60 patients (35%) who had strong evidence of increased pain within 3 months after TKI discontinuation.

**Characteristics of patients experiencing increased pain after stopping tyrosine kinase inhibitors**

There were no statistically significant differences in baseline characteristics of patients who did and did not have increased pain within 3 months (Table 1), including age or the particular TKI the patient had been taking prior to discontinuation. Of the 60 patients with evidence of increased pain within 3 months, at 4 years of follow-up, 40

---

**Table 2.** Pain within 3 months of tyrosine kinase inhibitor discontinuation.

| Physician-reported pain-related AE | Patient-reported increased muscle/joint pain (1+) (N=172) | Patient-reported increased muscle/joint pain (2+) (N=172) | Added medication for pain (N=154) | Patient-reported increased muscle/joint pain (2+) or added medication for pain (N=172) |
|-----------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------|-----------------------------------------------|
| No, N (%)                         | 54 (31.4)                                                | 122 (70.9)                                               | 108 (70.1)                      | 112 (65.1)                                   |
| Yes, N (%)                        | 11 (6.4)                                                 | 28 (16.3)                                                | 28 (18.2)                       | 24 (14.0)                                    |
| Total, N (%)                      | 65 (37.8)                                                | 150 (87.2)                                               | 136 (88.3)                      | 136 (79.1)                                   |

Note: 18 patients were missing data on medication, 14 of whom because they had restarted a tyrosine kinase inhibitor (TKI). AE: adverse events.

**Table 3.** Agreement between patient- and physician-reported musculoskeletal pain in first 3 months after tyrosine kinase inhibitor discontinuation (N=172).

| Maximum grade of physician-reported pain-related AE | Increase in patient-reported muscle/joint pain after TKI discontinuation |
|----------------------------------------------------|------------------------------------------------------------------------|
| No increase*                                       | +1                       | +2                      | +3                      | Total                                        |
| None, N (%)                                        | 54 (31.6)                | 68 (39.8)               | 14 (8.8)               | 1 (0.6)                                      | 137 (79.7)                                   |
| Mild, N (%)                                        | 7 (4.1)                  | 14 (8.2)                | 4 (2.3)                | 0                                             | 25 (14.5)                                    |
| Moderate, N (%)                                     | 2 (1.2)                  | 3 (1.8)                 | 2 (1.2)                | 1 (0.6)                                      | 8 (4.7)                                      |
| Severe, N (%)                                       | 1 (0.6)                  | 0                       | 0                      | 0                                             | 1 (0.6)                                      |
| Missing, N (%)                                      | 1 (0.6)                  | 0                       | 0                      | 0                                             | 1 (0.6)                                      |
| Total, N (%)                                        | 65 (37.8)                | 85 (49.7)               | 20 (11.7)              | 2 (1.2)                                      | 172 (100.0)                                  |

*No increase includes patients with no change as well as those with decreased pain. TKI: tyrosine kinase inhibitor; AE: adverse events.
(66.7%) had molecular relapse-free survival and 37 (61.7%) had sustained TFR, similar to the rates for patients who did not have increased pain within 3 months (64.0% molecular relapse-free survival and 60.4% TFR, Online Supplementary Figure S1).

**Trajectories of pain after stopping tyrosine kinase inhibitors**

**Self-reported musculoskeletal pain**

Figure 1 displays the distribution of self-reported musculoskeletal pain over time by TFR, among patients who had an indicator of increased pain after TKI discontinuation. The black line represents the best estimated pain trajectory for patients who experienced an increase in pain after TKI discontinuation. Both the observed (blue) line and the model-adjusted (black) line (which accounts for missing data) show an average increase in pain in the first 3 months that then decreases over time, returning to the baseline level by 6 months and further decreasing after that. Importantly, by 12 months, half of patients on TKI as well as more than half of patients off TKI reported little-to-no musculoskeletal pain (Figure 2). By 24 months this had increased to about three-quarters of patients who reported little-to-no pain.

![Figure 1. Trajectory of patient-reported musculoskeletal pain among patients with increased pain after tyrosine kinase inhibitor discontinuation (N=60). Note: blue diamonds and line indicate observed average; black line is the predicted trajectory for patients who do not restart a tyrosine kinase inhibitor (TKI) based on a piecewise mixed-effects ordinal logistic regression model.](image1)

![Figure 2. Proportions of patients with well-controlled pain off and on a tyrosine kinase inhibitor over time (N=60). TKI: tyrosine kinase inhibitor.](image2)
**PROMIS pain interference**

Figure 3 displays the distribution of pain interference scores over time by TFR, among patients who had an indicator of increased pain after TKI discontinuation. As with the single musculoskeletal pain item, there was an increase in pain interference after TKI discontinuation that peaked at 3 months and then decreased again. By 12 months, more than half of patients on TKI as well as three-quarters of patients off TKI reported little-to-no pain interference (Figure 2).

**Restarting TKI because of pain**

Three patients (1.7%) restarted a TKI due to withdrawal syndrome of pain. All three patients had physician-reported pain-related AE by 3 months and none reported starting a new medication for pain. The observed trajectories of patient-reported pain for these patients are shown in Figure 4. All demonstrate an increase in pain or sustained high level of pain after TKI discontinuation, followed by a decrease in patient-reported pain after restarting a TKI. They also show variation in patient-reported pain scores during both periods (on and off TKI). These patients restarted a TKI at 3 months, 7 months, and 12 months.

**Discussion**

In this large, multi-center trial, 26% of patients had a physician-reported pain-related AE, in line with the 10-50% with physician-reported pain-related AE in previous studies. When including patient-reported indicators of increased pain, 35-72% of patients had increased pain in the first 3 months after TKI discontinuation. We did not observe differences in pain after TKI discontinuation by type of TKI.

An important question for patients who experience increased pain after TKI discontinuation is whether resumption of a TKI will reduce pain more effectively than remaining off the TKI. Our data provide some insight into this question, because the 60 patients who experienced increased pain within 3 months of discontinuation included patients who did and did not restart a TKI. Almost all who restarted a TKI did so because of disease recurrence. We found that trajectories of musculoskeletal pain and pain interference showed similar patterns of improvement among patients who did and did not restart a TKI. Furthermore, the percentage of patients with well-controlled pain was similar for both groups of patients, suggesting that for patients who have increased pain after TKI discontinuation, pain should decrease again over time. The three patients who resumed a TKI because of increased pain evidenced similar trajectories of pain as the other patients who remained off TKI or restarted because of recurrence. Together, these data suggest that many patients in TFR who experience an increase in pain after stopping TKIs are likely to experience reductions in pain over time without having to restart a TKI. Whereas resuming a TKI may be necessary for some, other approaches to manage pain should be tried so that patients can remain in TFR when possible.

In previous studies, correlations between clinician-reported symptomatic AE and PRO measures have been shown to be moderate at best. In the LAST study, we also found moderate agreement. Over 60% of LAST patients reported any increase in musculoskeletal pain in the first 3 months after TKI discontinuation.
3 months after TKI discontinuation, while 13% of patients reported a 2- or 3-level increase in musculoskeletal pain, and 12% added a medication for pain relief. Using the threshold of a ≥ 2 level increase, there was an overall agreement of 75% between patients and physicians, with the data suggesting physicians reported fewer pain increases and less severe pain increases than patients did. There are a few possible explanations for discrepancies in patient and physician reports. First, patients have direct access to their own pain, whereas physicians have indirect access through observation and conversation with the patient. Second, patient reports and physician AE reports were made on different measurement scales. Third, physicians reported on pain that emerged after TKI discontinuation whereas changes in self-reported pain were based on repeated assessments of pain, reported using a recall period of 7 days.

It is important to consider these findings in the context of previously published findings from the LAST study. The majority of patients reported improvements in fatigue and diarrhea and in social functioning, but there were no corresponding improvements in physical function, which may seem surprising. One hypothesis for this is that while reduced fatigue and diarrhea may be sufficient to improve someone’s ability to participate in social roles and activities, it may not be enough to increase their physical function without a concerted effort to increase physical activity. Interventions to increase physical activity have been successful in many other oncologic settings. TKI discontinuation may represent an opportunity to encourage patients to increase their physical activity, taking advantage of the expected improvement in symptoms. This may also serve to mitigate the potential increase in musculoskeletal pain.

LAST patients were representative of the current TKI prescribing patterns in the US, with 59% of patients receiving imatinib. The rate of molecular recurrence in LAST was similar to other studies. That said, our sample was drawn from academic medical centers and may not be representative of all patients treated for CML. Self-reported musculoskeletal pain was measured using a single item that might have had limited precision, though the pain trajectory over time was very similar to the multi-item PROMIS Pain Interference assessment. Patients self-reported the changes in prescription and over-the-counter medications at 3 months after TKI discontinuation; we did not verify prescriptions. Finally, this was a group of patients who had been on therapy for nearly 7 years, so they were most likely to have been tolerating their medications well. Assessing the benefits of TKI discontinuation with regard to musculoskeletal pain is complicated. In the initial few months, the benefit of TKI discontinuation may be masked by the onset of TKI withdrawal syndrome. Our study has demonstrated that musculoskeletal pain improves with time after TKI discontinuation. For patients who experience increased pain, behavioral or cognitive approaches to managing musculoskeletal pain should be considered. In addition, given that TFR is associated with decreased fatigue, increased physical activity to improve musculoskeletal symptoms may be an effective modality to decrease pain. Finally, the use of analgesics and/or anti-inflammatory pain medication may help control pain. Additional studies to elucidate the mechanism of increased joint pain are warranted.

Disclosures
KEF reports receiving personal fees from Inhibikase and Pfizer and grants to her institution from Novartis outside...
References

1. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851-2857.

2. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003;21(11):2138-2146.

3. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.

4. Efficace F, Cardoni A, Cottone F, Vignetti M, Mandelli F. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res. 2013;37(2):206-213.

5. Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol. 2016;34(36):4323-4328.

6. Flynn KE, Mauro MJ, George G, et al. Patients’ perspectives on the definition of cure in chronic myeloid leukemia. Leuk Res. 2019;80:40-42.

7. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.

8. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298-305.

9. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.

10. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424-430.

11. Mahon F-X, Rea D, Guilhot J, et al. Long term follow-up after imatinib cessation for patients indeep molecular response: the update results of the STIM1 study. Blood. 2013;122(21):255.

12. Rea D, Rousselot P, Guilhot Fo, et al. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood. 2012;120(9):916.

13. Oh YJ, Choi SY, Lee S-E, et al. Results from the Korean Imatinib discontinuation study (KIDS): updated data with 14-month median follow up. Blood. 2013;122(21):4003.

14. Zang DY, Lee WS, Mun Y-C, et al. Long-term follow-up after treatment discontinuation in patients with chronic myeloid leukemia: the Korean Imatinib Discontinuation (KID) study. Blood. 2018;132(Suppl 1):S4252.

15. Mahon F-X, NicoliñI FE, Noël M-P, et al. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood. 2013;122(21):654.

16. Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with

ARTICLE - Pain after TKI discontinuation in CML

K. E. Flynn et al.

the submitted work. EA reports receiving personal fees from Novartis, Bristol Myers Squibb, and Takeda and grants to his institution from Novartis and Takeda outside the submitted work. NPS reports receiving funding to his institution from Bristol-Myers Squibb outside the submitted work. KPW drafted the manuscript; all authors critically revised the manuscript; KEF and EA obtained funding.

Contributions
KEF, EA and KPW developed the concept and design of the study; all authors acquired and interpreted data; KEF, LL and KPW performed statistical analysis; KEF, EA, LL and KPW drafted the manuscript; all authors critically revised the manuscript.

Funding
This study was supported by grant R01 CA184798 from the National Cancer Institute. The content is solely the responsibility of the authors and does not represent the official views of the National Cancer Institute.

Data-sharing statement
The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.

the submitted work. EA reports receiving personal fees from Novartis, Bristol Myers Squibb, and Takeda and grants to his institution from Novartis and Takeda outside the submitted work. NPS reports receiving funding to his institution from Bristol-Myers Squibb outside the submitted work. JPR reports receiving personal fees from Novartis, Bristol Myers Squibb, Takeda, Amgen, Cytogen, Bio-Rad, Adaptive, and SeaGen outside the submitted work. JP-I reports receiving personal fees from Janssen, AbbVie, AstraZeneca, Novartis, Pfizer, and Takeda outside the submitted work. VK reports receiving personal fees from Novartis and Pfizer outside the submitted work. RAL reports receiving grants and personal fees from Novartis and Celgene; personal fees from Bristol Myers Squibb, Takeda, Amgen, CVS/Caremark, Epizyme, AstraZeneca, and Agios; and grants from Forty Seven, Rafael Pharmaceuticals, Astellas, Daiichi Sankyo, and Cellectis, outside the submitted work; in addition, RAL had a patent to UptoDate Inc with royalties paid. JET reports receiving grants from Novartis and Bristol Myers Squibb outside the submitted work. VGO reports receiving personal fees from Bristol Myers Squibb, Takeda, Novartis and Pfizer outside the submitted work. MJM reports personal fees and research funding from Novartis Oncology and Bristol Myers Squibb; personal fees from Takeda and Pfizer; and research funding from Sun Pharma/SPARC outside the submitted work. JC reports grants to his institution and personal fees from Novartis, Pfizer, Sun Pharma and Takeda; and grants from BMS outside the submit work. No other disclosures were reported.

Data-sharing statement
The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.
chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42-50.
17. Schoenbeck KL, Atallah E, Lin L, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022;114(1):160-164.
18. Kota V, Atallah E. Musculoskeletal pain in patients with chronic myeloid leukemia after tyrosine kinase inhibitor therapy cessation. Clin Lymphoma Myeloma Leuk. 2019;19(8):480-487.
19. Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669-3676.
20. Efficace F, Rosti G, Aaronson N, et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014;99(4):788-793.
21. Atallah E, Schiffer CA, Weinfurt KP, et al. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018;18(1):359.
22. Cella D, Riley W, Stone A, et al. The PatientReported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179-1194.
23. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757.
24. Schoenbeck KL, Atallah E, Lin L, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022;114(1):160-164.
25. Efficace F, Baccarani M. Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: who can benefit the most? J Natl Cancer Inst. 2022;114(1):9-11.
26. Kiss N, Baguley BJ, Ball K, et al. Technology-supported self-guided nutrition and physical activity interventions for adults with cancer: systematic review. JMIR Mhealth Uhealth. 2019;7(2):e12281.
27. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A systematic review of exercise systematic reviews in the cancer literature (2005-2017). PM&R. 2017;9(9):S347-S384.